No Image 01Jun

by

Profiles of Four New Stock-Billionaires

No Image 01Jun

by

IPOs spawn instant billionaires

No Image 01Jun

by

G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

No Image 01Jun

by

Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

No Image 01Jun

by

INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

No Image 01Jun

by

Oscotec shares rebound on launch of US clinical trial

No Image 01Jun

by

More than half of Korean biopharma firms view R&D investments as assets.

No Image 01Jun

by

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

No Image 01Jun

by

"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

No Image 01Jun

by

Yuhan ups investment in biotechs for immuno-oncology drug push

No Image 01Jun

by

Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

No Image 01Jun

by

Oscotec`s acute leukemia treatment wins orphan drug status from FDA